What is the difference between ALIROCUMAB and EZETIMIBE?

ALIROCUMAB is a PCSK9 Inhibitor and EZETIMIBE is a Cholesterol Absorption Inhibitor. They reach a similar treatment goal through different pharmacological mechanisms, which is why one may be tolerated by a patient who could not tolerate the other.

Is Praluent the same as EZETIMIBE?

No. Praluent (ALIROCUMAB) and EZETIMIBE (EZETIMIBE) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, ALIROCUMAB or EZETIMIBE?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from ALIROCUMAB to EZETIMIBE?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

ALIROCUMAB vs EZETIMIBE

Compare ALIROCUMAB (Praluent) and EZETIMIBE (EZETIMIBE) — clinical data, side effects, and patient experiences.

ALIROCUMAB

Praluent · PCSK9 Inhibitor

How it works

12.1 Mechanism of Action Alirocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein (...

Approved for

1 INDICATIONS AND USAGE PRALUENT ® is indicated: To reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death

myocardial infarction

stroke

myocardial infarction

SubcutaneousTablet

EZETIMIBE

EZETIMIBE, Zetia · Cholesterol Absorption Inhibitor

How it works

12.1 Mechanism of Action Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe has been shown to...

Approved for

1 INDICATIONS AND USAGE Ezetimibe tablets are indicated: • In combination with a statin

or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible

as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia

and other LDL-C lowering therapies

OralTablet

Quick Comparison

ALIROCUMABEZETIMIBE

Drug Class

PCSK9 Inhibitor

Cholesterol Absorption Inhibitor

Route

Subcutaneous

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ALIROCUMAB

Muscle Pain

>10%

Injection Site Pain

1-10%

Joint Pain

1-10%

Fatigue

1-10%

Limb Pain

1-10%

Diarrhea

1-10%

Headache

1-10%

Cough

0.1-1%

EZETIMIBE

Fatigue

1-10%

Nausea

1-10%

Muscle Pain

1-10%

Drug Not Working

1-10%

Diarrhea

1-10%

Dizziness

1-10%

Shortness of Breath

1-10%

Headache

1-10%

FDA Warnings

ALIROCUMAB

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions: hypersensitivity vasculitis, angioedema, and other hypersensitivity reactions requiring hospitalization, have been reported with PRALUENT treatment
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to alirocumab or any excipient in PRALUENT [see Contraindications (4) ]

EZETIMIBE

5 WARNINGS AND PRECAUTIONS • Risks Associated with Combination Treatment with a Statin, Fenofibrate, or Other LDL-C Lowering Therapies : Refer to the Prescribing Information of these products for a description of their risks including, but not limited to, the warnings and precautions
In post-marketing reports, most patients who developed rhabdomyolysis were taking a statin or other agents known to be associated with an increased risk of rhabdomyolysis, such as fibrates
1 Risks Associated with Combination Treatment with a Statin, Fenofibrate, or Other LDL-C Lowering Therapies If ezetimibe is administered with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for a description of their risks including, but not limited to, the warnings and precautions [see Contraindications (4) ]
In post-marketing reports, most patients who developed rhabdomyolysis were taking a statin or other agents known to be associated with an increased risk of rhabdomyolysis, such as fibrates

Community Sentiment Analysis

Based on 3 Reddit discussions

ALIROCUMAB

positive

0 threads

EZETIMIBE

33%

positive

3 threads

Community Discussions

No community discussions found for ALIROCUMAB yet.

Community Discussions

3 Reddit threads analysed for EZETIMIBE

Overall Sentiment

Mixed

Comparison Threads

Avg Post Score

6 upvotes

Comparison Threads

Threads directly comparing EZETIMIBE to other medications

Lipid hypothesis vs pleomorphic effects of statins

A lot of people feel it either goes one way or the other. Strong feelings in cardiology toward one or the other, but maybe they aren't mutually exclusive theories... How do you feel as a pharmacist? Are you cool seeing patients on statin + ezetimibe in primary prevention? Okay with patients on ezet

r/pharmacy128y ago

Patient Experiences (r/pharmacy, r/AskDocs & more)

Cholesterol start with statin+ezetimibe?

Hello, I work in Italy and recently I see more and more patients that are prescribed to start therapy for high cholesterol with the combination statin + ezetimibe. When I studied, I was tought to use maximally tollerated statin dose and then add ezetimibe if necessary. The latest guideline I found i

r/pharmacy15132y ago

Australian pharmacists/ techs doing DAA packs- a question

When you have to pack combo-pack meds (eg. rosuvastatin / ezetimibe (Rosuzet/ Ezalo) where the pack is two separate tablets daily instead of a single tablet with both medications, what is your preferred method for charting in the software? Both seem very imperfect and cause confusion with my patient

r/pharmacy211y ago

Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.

ALIROCUMAB vs EZETIMIBE: What You Should Know

Key Differences

ALIROCUMAB is a PCSK9 Inhibitor, while EZETIMIBE belongs to the Cholesterol Absorption Inhibitor class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. ALIROCUMAB is administered via Subcutaneous, whereas EZETIMIBE uses Oral. Route of administration can affect onset of action and patient adherence.

Safety Considerations

ALIROCUMAB carries 4 FDA warnings. EZETIMIBE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

BEMPEDOIC ACID AND EZETIMIBE vs EZETIMIBE→ALIROCUMAB vs Atorvastatin→Atorvastatin vs EZETIMIBE→ALIROCUMAB vs Rosuvastatin→EZETIMIBE vs Rosuvastatin→ALIROCUMAB vs SIMVASTATIN→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

ALIROCUMAB: DailyMed label · FAERS adverse events · ClinicalTrials.gov
EZETIMIBE: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

ALIROCUMAB vs EZETIMIBE

Compare ALIROCUMAB (Praluent) and EZETIMIBE (EZETIMIBE) — clinical data, side effects, and patient experiences.

ALIROCUMAB

Praluent · PCSK9 Inhibitor

How it works

12.1 Mechanism of Action Alirocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein (...

Approved for

1 INDICATIONS AND USAGE PRALUENT ® is indicated: To reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death

myocardial infarction

stroke

myocardial infarction

SubcutaneousTablet

EZETIMIBE

EZETIMIBE, Zetia · Cholesterol Absorption Inhibitor

How it works

12.1 Mechanism of Action Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe has been shown to...

Approved for

1 INDICATIONS AND USAGE Ezetimibe tablets are indicated: • In combination with a statin

or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible

as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia

and other LDL-C lowering therapies

OralTablet

Quick Comparison

ALIROCUMABEZETIMIBE

Drug Class

PCSK9 Inhibitor

Cholesterol Absorption Inhibitor

Route

Subcutaneous

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ALIROCUMAB

Muscle Pain

>10%

Injection Site Pain

1-10%

Joint Pain

1-10%

Fatigue

1-10%

Limb Pain

1-10%

Diarrhea

1-10%

Headache

1-10%

Cough

0.1-1%

EZETIMIBE

Fatigue

1-10%

Nausea

1-10%

Muscle Pain

1-10%

Drug Not Working

1-10%

Diarrhea

1-10%

Dizziness

1-10%

Shortness of Breath

1-10%

Headache

1-10%

FDA Warnings

ALIROCUMAB

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions: hypersensitivity vasculitis, angioedema, and other hypersensitivity reactions requiring hospitalization, have been reported with PRALUENT treatment
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to alirocumab or any excipient in PRALUENT [see Contraindications (4) ]

EZETIMIBE

5 WARNINGS AND PRECAUTIONS • Risks Associated with Combination Treatment with a Statin, Fenofibrate, or Other LDL-C Lowering Therapies : Refer to the Prescribing Information of these products for a description of their risks including, but not limited to, the warnings and precautions
In post-marketing reports, most patients who developed rhabdomyolysis were taking a statin or other agents known to be associated with an increased risk of rhabdomyolysis, such as fibrates
1 Risks Associated with Combination Treatment with a Statin, Fenofibrate, or Other LDL-C Lowering Therapies If ezetimibe is administered with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for a description of their risks including, but not limited to, the warnings and precautions [see Contraindications (4) ]
In post-marketing reports, most patients who developed rhabdomyolysis were taking a statin or other agents known to be associated with an increased risk of rhabdomyolysis, such as fibrates

Community Sentiment Analysis

Based on 3 Reddit discussions

ALIROCUMAB

positive

0 threads

EZETIMIBE

33%

positive

3 threads

Community Discussions

No community discussions found for ALIROCUMAB yet.

Community Discussions

3 Reddit threads analysed for EZETIMIBE

Overall Sentiment

Mixed

Comparison Threads

Avg Post Score

6 upvotes

Comparison Threads

Threads directly comparing EZETIMIBE to other medications

Lipid hypothesis vs pleomorphic effects of statins

r/pharmacy128y ago

Patient Experiences (r/pharmacy, r/AskDocs & more)

Cholesterol start with statin+ezetimibe?

r/pharmacy15132y ago

Australian pharmacists/ techs doing DAA packs- a question

r/pharmacy211y ago

Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.

ALIROCUMAB vs EZETIMIBE: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.